Recombinant Human CD161/KLRB1 protein (rFc Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg1788
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human CD161 protein Gln67-Ser225 (Accession# Q12918) with a rabbit IgG Fc tag at the C-terminus. |
| GeneID | 3820 |
| Accession | Q12918 |
| PredictedSize | 44.8 kDa |
| SDS-PAGE | 50-68 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CD161 (KLRB1) is a clinical diagnostic marker predicting negative course of patients with gliomas. It plays prominent immune‐evading roles in glioma, and the expression of CD161 on CD8+ lymphocytes gradually increases during glioblastoma genesis. CD161 was shown to inhibit natural killer (NK) cell–mediated cytotoxicity of tumor cells, and CLEC2D (alternatively named lectin-like transcript 1; LLT1) was identified as its ligand.
References:
1.Di, Wang et al. Cancer science vol. 113,2 (2022): 756-769. 2.Mathewson, Nathan D et al.Cell vol. 184,5 (2021): 1281-1298.e26. 3.Alvarez Calderon, Francesca et al.Blood vol. 143,12 (2024): 1124-1138.